Mercator enrolls first patient in BTK vascular disease trial

Mercator MedSystems said today that the 1st patient was enrolled in its Tango clinical trial. The trial is evaluating Mercator’s Bullfrog micro-infusion device for the adventitial delivery of temsirolimus below the knee in patients with critical limb ischemia.

The Tango trial is the 4th ongoing clinical trial using the Bullfrog device in below the knee applications for patients with peripheral artery disease. Mercator said that outside of trials using its Bullfrog drug delivery system, there is only 1 other intravascular drug delivery tech, a paclitaxel-coated angioplasty balloon, being investigated in a U.S. study for BTK vascular disease.

Get the full story at our sister site, Drug Delivery Business News.

The post Mercator enrolls first patient in BTK vascular disease trial appeared first on MassDevice.

from MassDevice http://ift.tt/2q62FL0